

Citation for published version:

Fabrizio Schifano, G. Duccio Papanti, Laura Orsolini & John M. Corkery, 'Novel psychoactive substances: the pharmacology of stimulants and hallucinogens', *Expert Review of Clinical Pharmacology*, Vol 9 (7): 943-954, April 2016.

DOI:

<http://www.tandfonline.com/doi/abs/10.1586/17512433.2016.1167597>

Document Version:

This is the Accepted Manuscript version.

The version in the University of Hertfordshire Research Archive may differ from the final published version. **Users should always cite the published version of record.**

Copyright and Reuse:

This Manuscript version is distributed under the terms of the Creative Commons Attribution licence (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.

Enquiries

If you believe this document infringes copyright, please contact the Research & Scholarly Communications Team at rsc@herts.ac.uk



Novel Psychoactive Substances: the pharmacology of stimulants and hallucinogens

Fabrizio Schifano, Duccio G. Papanti, Laura Orsolini & John M. Corkery

To cite this article: Fabrizio Schifano, Duccio G. Papanti, Laura Orsolini & John M. Corkery (2016): Novel Psychoactive Substances: the pharmacology of stimulants and hallucinogens, Expert Review of Clinical Pharmacology

To link to this article: <http://dx.doi.org/10.1586/17512433.2016.1167597>



Accepted author version posted online: 17 Mar 2016.



Submit your article to this journal [↗](#)



View related articles [↗](#)



View Crossmark data [↗](#)

Publisher: Taylor & Francis

Journal: *Expert Review of Clinical Pharmacology*

DOI: 10.1586/17512433.2016.1167597

Review

Novel Psychoactive Substances: the pharmacology of stimulants and hallucinogens

Fabrizio Schifano, Duccio G. Papanti, Laura Orsolini, John M. Corkery

'Psychopharmacology; drug misuse; and novel psychoactive substances'

Research Unit; School of Life and Medical Sciences, University of Hertfordshire,
Hatfield, Herts, UK

Corresponding Author

Professor Fabrizio Schifano, MD, FRCPsych

Chair in Clinical Pharmacology and Therapeutics

Consultant Psychiatrist

University of Hertfordshire

Psychopharmacology, Drug Misuse and Novel Psychoactive Substances

Research Unit

School of Life and Medical Sciences

College Lane Campus

Hatfield, Herts

AL10 9AB (UK)

telephone: +44 (0)1707-286107

fax: +44 (0)1707-284506

mobile: +44 (0)753 4915035

email: F.Schifano@herts.ac.uk

Abstract

There are increasing levels of concern relating to the rapidly evolving novel psychoactive substances/NPS and web markets' scenarios. The paper aims at providing an overview of the clinical pharmacological issues related to some of the most popular NPS categories, e.g. stimulants and hallucinogens. NPS intake is typically associated with the imbalance of a complex range of neurotransmitter pathways/receptors, namely: dopamine; cannabinoid/CB1; and 5-HT_{2A}. The intake is almost invariably undetectable with standard screening tests. Hence, it may frequently occur that the acute management of NPS misusers will need to focus on decreasing levels of both self/outward-directed aggression and agitation. Benzodiazepines may be considered as first line treatment. Alternatively, propofol and/or antipsychotics can be administered. Focus will be as well on treatment of possible rhabdomyolysis and hyperthermia. Indeed, future studies should inform better tailored management/treatment strategies.

Key words

Novel psychoactive substances; Synthetic cannabimimetics; Synthetic cathinones; Hallucinogenic drugs; Phenethylamines; Psychiatric disturbances; Drug misuse.

Introduction

Over the last decade, the drug scenario has shown significant levels of changes, with the emergence of a range of novel psychoactive substances (NPS). NPS are typically defined as new narcotic/psychotropic drugs which are not controlled by the United Nations' 1961 Narcotic Drugs/1971 Psychotropic Substances Conventions, but which may pose a public health threat [1]. However, 'novel' typically refers to molecules that have recently become a reason of current/potential public health concern. At times, although misleading, the terms 'legal highs' or 'research chemicals' have been used as well to describe such substances, with the web playing a major role in shaping this unregulated market.[2]. Overall, there are increasing levels of concern about both the complex pharmacodynamics of these drugs and the appearance of acute/chronic medical and psychopathological manifestations associated with NPS intake.[1] A concurrent use of a range of different NPS, and/or medications, is frequently being reported and this may be a reason of further concern.

The present paper aims at providing an overview of the clinical pharmacological issues related to some of the most popular NPS categories, e.g. stimulants and hallucinogens (for a rapid overview, see Table 1).

Methods

We searched Medline/PubMed for studies using the terms "new psychoactive substances", "novel psychoactive substances", "legal highs", "designer drugs",

“research chemicals”, “smart drugs”, “emerging drugs of abuse”, “emerging drugs of misuse”, “stimulants”, “hallucinogenic drugs”, “psychedelics”, “synthetic cannabimimetics”, “synthetic cannabinoids”, and “spice”.

The search was filtered by “English and human” and limited by publication dates to the last five years. In total, 4159 references were identified; of these, 363 were considered potentially relevant. Some further 35 references were retrieved from specific websites identified by typing the index substance keywords on Google, with selection and analysis of fora posts/threads; and from national/international agencies’ reports. After a further thorough screening for eligibility, some 82 papers/documents had finally been considered here as suitable and consistent with the aims of the paper.

Stimulants: synthetic cathinones; 4-4'-DMAR; methylphenidate-like NPS; amphetamine-type stimulants; aminoindanes; and cocaine analogues

Synthetic cathinones

The only cathinones under international control (United Nations Convention on Psychotropic Substances 1971) are amfepramone, cathine, cathinone, mephedrone, methcathinone and pyrovalerone. Although mephedrone (4-methylmethcathinone) was originally synthesised in 1929, it first appeared on the drug scene in 2008, [3] and synthetic cathinones currently account for the second largest group of substances monitored by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Of the hundred or so cathinones notified to date to the EMCDDA, those which are a reason of

particular concern are: mephedrone; 4-MEC/4-Methylethcathinone; alpha-PVP/ α -pyrrolidinopentiophenone; flephedrone; MDPBP/3',4'-Methylenedioxy- α -pyrrolidinobutyrophenone; MDPV/ Methylendioxypropylvalerone; methedrone; methylone; naphyrone; pentedrone and pyrovalerone.

Simmler and colleagues[4] have identified three categories of cathinones: (a) substrates for the dopamine (DAT), serotonin (SERT) and norepinephrine/noradrenaline (NET) transporters with MDMA-like profiles, e.g. mephedrone, methylone, butylone, ethylone, 4-MEC; (b) monoamine transporter substrates with DAT-selective profiles similar to amphetamine and methamphetamine, e.g. cathinone, methcathinone, flephedrone. Naphyrone and 1-naphyrone have very high potencies and some degree of selectivity for DAT; and (c) non-substrate transporter inhibitors, e.g. MDPV.

Methcathinone (ephedrone) selectively generates a release of dopamine (DA) higher than that of serotonin (5-HT). MDPV is a DA selective uptake inhibitor, but selectively blocks the uptake of DA more than 5-HT, and presents with a high abuse potential.[5] MDPV inhibits monoamine uptake at the DA, 5-HT and norepinephrine (NET) transporters, similarly to cocaine.[6,7] The behavioural effects of mephedrone and MDPV are similar to methamphetamine and cocaine respectively, whilst methylone's are closer to MDMA.[8] MDPV, mephedrone, methcathinone, and naphyrone are potent NET inhibitors.[9]

Synthetic cathinones are typically sold as pills, capsules and powders. They are usually snorted/sniffed (insufflated), taken orally by 'bombing' (swallowing the powder wrapped in a cigarette paper), mixed in a drink, or through intravenous injecting.

Synthetic cathinones are often used by consumers for various reasons, including: hallucinogenic experiences, euphoria, mood enhancement, openness, empathy, mental clarity, stimulation, increased energy, and increased libido.[10] Mephedrone possesses a re-dosing risk due to half-life being as short as 1h.[11] By contrast, MDPV is thought to have a half-life of 3-5 h. Several different cathinones are often used together, and this could cause synergistic effects, e.g. as with MDPV and mephedrone. [9]

The most common cathinones' adverse reactions are restlessness and anxiety, ranging from mild agitation to severe psychosis. Furthermore, tachycardia, hypertension, abdominal pain, chills, flushing, sweating, hyperthermia, renal failure, rhabdomyolysis, and seizures can also be observed.[1,12-14] Paranoid ideation and mood disturbances have been observed in chronic users of both natural and synthetic cathinones.[13-16] Many synthetic cathinones users report tolerance, dependence and withdrawal symptoms.[17]

Injecting use of synthetic cathinones has emerged among specific sub-populations' segments of at least 10 EU countries.[18] In some areas in Europe (e.g. eastern Europe), such injectors account for more than half of all drug injectors, with problem drug users now switching from heroin. The intake of cathinones can occur with high frequency levels, e.g. up to 10-20 times injections per day. MDPV, mephedrone, and 4-MEC are all reported to be injected. A more recent development is the injecting of α -PVP in Ireland.[19]

Within the 'Chemsex' (e.g. the use of misusing drugs to increase levels of libido/sexual performances) context, drugs including synthetic

cathinones/mephedrone are described as having a significant influence on the risk-taking behaviour of 'men who have sex with men'/MSM population.[20]

Some 83 deaths involving synthetic cathinones had been registered by the end of 2014 in England and Wales.[21] Although most fatalities involved mephedrone, increasing numbers of α -PVP and pentedrone deaths are being reported in the EU. Cathinones are typically involved in hangings or other mechanical suicides.[13,14]

4,4'-dimethylaminorex (4,4'-DMAR)

4,4'-dimethylaminorex (4,4'-DMAR, "Serotoni"), a derivative of aminorex, is a powerful dopamine/noradrenaline releaser whilst inhibiting the SERT as well. It may be snorted, or ingested, to achieve levels of both elation and increased alertness. The relating anxiety/agitation may last for a number of hours, with the risk of increase in body temperature and cardiorespiratory problems. [22] "Serotoni" has recently been associated with some 35 fatalities in Europe.[1]

Methylphenidate-like NPS

Ethylphenidate (EPH; sold under a range of brandnames such as '*Burst*', '*El Blanco*', '*Gogaine*') is the ethyl-homologue of methylphenidate (MPH). It appeared in the UK market in 2011 and has now become one of the most popular NPS. Both EPH and MPH are stimulant drugs, being potent inhibitors of both DA and noradrenaline (NE) reuptake, although EPH is almost 5 times less potent against NE than DA, and MPH is less selective.[23] Other MPH-derived compounds have recently appeared on the market, such as 3,4-

dichloromethylphenidate (3,4-DCMP); methylnaphthidate (HDMP-28); propylphenidate; and isopropylphenidate. 3,4-DCMP is claimed to be more potent than MPH, with a slower onset of action and longer duration.[23]

HDMP-28 acts as a triple receptor re-uptake inhibitor (DA, NE, and 5-HT) in a manner similar to cocaine; it is also claimed to have several times the potency of MPH, but with a shorter duration of action.[23]

EPH can also be found as an extra ingredient in psychoactive compounds' mixtures, together with methiopropamine, ephedrine, phenylethylamine, and remaining stimulants.[23,24] EPH intake can occur orally, intranasally, rectally, or through intramuscular/intravenous injection. Commonly reported dosages are 10-100 mg for oral or intranasal administration, and 5-50 mg for injection.[25] The mean onset time for the EPH 'high' is around 15 minutes for intranasal, and 25 minutes for oral administration; the mean duration of the effects is 120 minutes for all routes of administration. It has been suggested that, at low doses, EPH encourages increased levels of motor/mental productivity, whilst at higher dosages this may result in a general lack of motor control.[26] EPH can be found in powder; crystalline; and tablet form.

Commonly reported effects reported by users include euphoria, stimulation/increased arousal, improved concentration, sociability, and sexual drive. Conversely, adverse effects reported include muscle tension, palpitations, sweating, appetite loss, anxiety/restlessness, insomnia, paranoia, and auditory/visual hallucinations.[24] EPH intake has been associated with bizarre/erratic and violent behaviour, suicidality, psychosis, and clinical worsening of paranoid schizophrenia.[23] Tolerance to EPH has been

described. Many users report a concurrent intake of a range of substances, and in particular of sedative drugs such as alcohol, benzodiazepines and/or opiates used as 'downers', together with EPH. A 'crash'-like phase after the end of an EPH binge session, with a period of mood lowering and fatigue, has been described.[27] As it might be expected from a short half-life stimulant which boosts DA levels, users report a strong urge/compulsion to re-dose.[23,27,28] A significant outbreak of severe soft-tissue infections among drug users who report injecting EPH repeatedly has been recently identified.[23] Twenty-eight fatalities associated with analytically confirmed EPH ingestion, mostly in combination with other drugs, have been described.

Amphetamine-type stimulants/novel stimulants

Amphetamine-type substances (ATS) include: PMA (4-methoxyamphetamine); PMMA (4-methoxymeth-amphetamine); 4-MTA (4-methylthioamphetamine/"flatliners"); DMA (2,5-dimethoxyamphetamine); diclofensine; methiopropamine/MPA; etc.[1,29]

PMA and PMMA (aka 'red Mitsubishi'/'pink ecstasy'/'Mitsubishi turbo'/'Dr.

Death) are similar to MDMA, although these molecules are already extremely active at lower doses. They may determine a fatal rise in body temperature, euphoria, a sense of full energy, an amplification of sounds/colours and feelings of love/sociability. An increasing number of fatalities have been described following their consumption.[30]

Diclofensine is a stimulant that acts as a DA/NE/5-HT reuptake inhibitor.[31] It was originally developed as an antidepressant, but eventually abandoned due to possible concerns about its potential for abuse.[32]

Methiopropamine (MPA; 'Blow') was firstly synthesized in 1942 but advertised on the Internet as a 'research chemical' in late 2010.[33-36] It acts as a selective NE/DA reuptake inhibitor.[37] It may be ingested, snorted, or smoked. At low doses, it is a stimulant associated with mild euphoria, alertness, sexual arousal, loss of appetite, tachycardia, anxiety, etc. Adverse effects include a significant hangover after extended use with nausea, headache, dizziness, lack of energy, skin irritation and difficulty urinating.[1]

Aminoindanes

The UNODC [38] reports that up May 2015 the most commonly reported aminoindanes were 5,6-methylenedioxy-2-aminoindane (MDAI; 'MDAI gold'); 5-iodo-2-aminoindane (5-IAI); and 2-aminoindane (2-AI; *Blurberrys*, 'Groove-e', 'Pink Champagne'). Other aminoindanes available as NPS include: *N*-methyl-2-aminoindane (*N*-methyl-2AI; NM-2AI); 1-aminoindane; and ETAI (*N*-ethyl-5-trifluoromethyl-2-aminoindane). Although some of these molecules are controlled in specific countries, none of them are subject to control under the UN international Drug Conventions. The aminoindanes' potential to affect serotonin release and re-uptake [39] is likely to be associated with the ability to engender entactogenic and empathogenic effects akin to those of MDMA.[40]

Most aminoindanes are available from a range of sources, including the web, as tablets, powder, and capsules/tablets which can be either ingested or snorted.

Aminoindanes are used by consumers in search of a range of psychoactive effects, including: hallucinogenic experiences, euphoria, mood enhancement, openness, empathy, mental clarity, stimulation, increased energy, and increased libido.[41]

Aminoindanes are reported to cause eye and skin irritation, as well as gastrointestinal disturbances with nausea, vomiting/diarrhoea, and respiratory tract concerns. Three deaths associated with MDAI use, either alone or in combination, were identified in the UK during 2011-2012, all involving symptoms consistent with serotonin syndrome.[42]

Synthetic cocaine analogues

Dimethocaine and 4-fluorotropacocaine (*p*FBT), typically found as white powder, act as DA reuptake inhibitors, resulting in mild stimulant effects. Similar to cocaine, both substances are being insufflated since following ingestion they would be hydrolysed by the digestive system esterases.

Dimethocaine users report a short-lasting rush, together with levels of increased attention/concentration, talkativeness, and the desire to re-dose.

Adverse/unwanted effects include peripheral vasoconstriction, tachycardia, diaphoresis, muscle twitching, nausea, and vomiting.[41] *p*FBT is anecdotally reported to cause hypertension, tachycardia, anxiety and temporary psychosis.[41] Further cocaine analogues include RTI-111 (e.g. a potent

stimulant acting as an inhibitor of 5-HT, DA and NE reuptake[43]); RTI-121 and RTI-126. RTI-121 is a potent/long-lasting stimulant acting as a selective DA reuptake inhibitor.[44] RTI-126,[45] on the other hand, may present with a potency which is 5-fold higher than that of cocaine. When snorted, these compounds are associated with alertness, euphoria, talkativeness, insomnia, prolonged residual tension/anxiety, and crash-like symptoms.[1]

Hallucinogens: synthetic cannabimimetics; psychedelic phenethylamines; and tryptamines

Synthetic cannabimimetics

Synthetic cannabimimetics (SC; 'Spice') were first detected in Europe towards the end of 2008 and, at the time of writing, constitute the largest group (about 30%) of NPS monitored by the EMCDDA. SC belong to a range of chemically different families of compounds. Some are cannabinoid receptors' agonists whilst others are compounds targeting enzymes involved in the metabolism and transportation of endocannabinoids.[46] Many SC contained in Spice drugs are full-agonists, possess large levels of receptors' affinity, and hence elicit maximal activity at cannabinoid receptors.[47] Conversely, THC effects in cannabis are modulated/dampened by the presence of other natural compounds such as terpenoids, cannabidiol and tetrahydrocannabivarin,[46] but no such 'modulating' compounds are generally detected in Spice products.[48] Several SC have been found to interact with a range of remaining receptors, including: 5-HT, nicotinic acetylcholine, glycine, and/or

ionotropic glutamate (NMDA), and it is possible that SC produce their complex effects through their actions at non-cannabinoid receptors as well.[48] A number of SC compounds incorporate indole-derived moieties active on 5-HT receptors, either as components of the structure or as substituents. It has been suggested that, at high doses, SC compounds may also possess some monoamine oxidase, and 5-HT reuptake, inhibitory properties.[49] These complex pharmacodynamic elements may further increase the risk of serotonin syndrome occurrence in SC misusers.[10,46] Furtherly, it has been suggested that the chronic activation of CB-2 receptors results in the upregulation of 5-HT_{2A} receptors in the prefrontal cortex of mice.[50] Modification in 5-HT_{2A} receptors' neurotransmission has been associated with hallucinations/delusions/psychosis.[51]

'Spice' preparations are composed by both a dried plant base, to mimic the 'grass effect' of female cannabis dried inflorescences, and a mixture of SC which are sprayed on it. SC dispersed in the grass preparation look like hashish, with capsules and e-liquid formulations being available as well. SC have also been found in tablets and sprayed on herbal cannabis. SC can be found on the web, from 'head-shops', gas stations, and from an ever expanding range of other outlets.[52]

Their intake can occur through inhalation from a joint/bhong/pipe or using a vaporizer. Other ways of intake include: insufflation, oral ingestion, rectal administration and injection.[1] Misusers are often young males, choosing Spice instead of cannabis for its low cost; favourable legal status; [41] easy availability; mis-perception that SC are natural, and not synthetic, molecules;

and undetectability in routine urine screening tests.[53,54] The non-detectability of SC make also Spice very attractive for sub-populations undergoing regular drug tests.[10]

Spice products are almost always laced with multiple SC in a single preparation.[1] Hence, there is a potential for drug–drug interactions between multiple SC in a single product, and this may contribute to the abuse-related and synergistic effects of these compounds. Some SC metabolites, furthermore, retain levels of both affinity and activity for CB-1 receptors, hence contributing to the toxicity of the products.[55] The recent trend of SC fluorination may increase the compounds' lipophilicity, hence promoting the absorption through biological membranes/blood brain barrier, possibly enhancing the SC overall toxicity.[55]

The total lack of product quality control may lead to significant differences in concentration ('hot-spots') of SC present in herbal incenses or e-liquids.[46,55] In comparison with cannabis, use of SC may be characterized by quicker 'kick off' effects; significantly shorter duration of action; larger levels of hangover effects; and more intense visual hallucinations, paranoid feelings, and behavioural dyscontrol.[46,56] The acute SC intoxication is characterized by a short-lived clinical picture with reported signs/symptoms of elevated heart rate/blood pressure levels; visual/auditory hallucinations; mydriasis; agitation/anxiety; hyperglycaemia; dyspnoea/tachypnoea; and nausea/vomiting.[1]

Other psychiatric and neurological effects include: suicidal ideation/self-injurious behaviour; aggressive behaviour; panic attacks; cognitive

impairment; thought disorganisation; psychosis; agitated/excited delirium; nystagmus; seizures; hyperemesis; encephalopathy; acute kidney injury; rhabdomyolysis; hyperthermia; serotonin syndrome; toxic hepatitis/liver failure; coma; severe dysrhythmias/cardiotoxic effects; and stroke.[1,56]

Long-term SC misuse may also be associated with tolerance, dependence, and a severe prolonged withdrawal syndrome, characterized by drug craving, tachycardia, tremor, profuse sweating and diarrhoea, nightmares/insomnia, headache, anxiety/irritability, mood swings, feelings of emptiness/depressive symptoms, and somatic complaints.[1] SC intake has been associated with a range of psychotomimetic disturbances (e.g. paranoia, delusions, hallucinations), the occurrence of florid/acute transient psychosis, relapse/worsening of a pre-existing psychosis, persistent psychotic disorder/'Spiceophrenia'; [56] and relapse of a pre-existing bipolar disorder.[57] A number of deaths have been related to SC ingestion, either on their own or in combination, in analytically confirmed reports.[1] Very recently, a phase I clinical trial for the development of a painkiller drug akin the ones found in Spice was abruptly terminated due to severe neurological adverse effects and one death among a number of human volunteers.[58]

Psychedelic phenethylamines

Phenethylamines include a wide range of natural or synthetic substances which own psychostimulant, entactogenic and hallucinogenic effects. Mescaline, isolated from peyote cactus (*Lophophora williamsii*) and traditionally chewed by Indians in Mexico as a religious sacrament, represents the prototype

psychoactive phenethylamine compound. A variety of methoxylated amphetamine compounds are derived by mescaline, and include: TMA (3,4,5-trimethoxyamphetamine); DOM (3-methoxy-4,5-methylenedioxyamphetamine); DOET (2,4,4-trimethoxyamphetamine); DOI (4-iodo-2,5-dimethoxyamphetamine); DOC (4-chloro-2,5-dimethoxyamphetamine), etc. [59] Alongside these substances, the group of phenethylamines also include a total of 179 'classical' phenethylamines, such as: MDMA (3,4-methylenedioxymethamphetamine)-like drugs (e.g. MDA [3,4-methylenedioxy-amphetamine]; MDEA [3,4-methylenedioxyethamphetamine]; MBDB [N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine]; and the latest generation phenethylamine derivatives: e.g. 'Bromodragonfly' (1-(8-bromobenzo[1,2-b; 4,5-b']difuran-4-yl)-2-aminopropane); NBOMe derivatives; indanes; benzofurans; and the class of 2C- molecules such as 2,5-dimethoxy-4-bromophenethylamine (2C-B), 2,5-dimethoxy-4-iodophenethylamine (2C-I); and 2,5-dimethoxy-4-ethylphenethylamine (2C-E). [1]

Bromo-Dragonfly (aka '*DOB-Dragonfly*'/'*3C-Bromo-Dragonfly*' [60]) displays a high affinity for 5-HT_{2A}, 5-HT_{2B}, and 5-HT_{2C} receptors. [61] Its effects are associated with long-standing hallucinations, mood elevation, paranoid ideation, confusion, anxiety and flashbacks. In addition, both a number of related acute intoxications with convulsions, respiratory problems, liver and kidney failure, severe vasoconstriction, and fatalities have been described. [60]

The 2C-series compounds, including: 2,5-dimethoxy-4-bromophenethylamine (2C-B; '*Nexus*'), but also 2,5-dimethoxy-4-methylphenethylamine (2C-D), 2,5-dimethoxy-4-ethylphenethylamine (2C-E), 2,5-Dimethoxy-4-

nitrophenethylamine (2C-N), 2,5-Dimethoxyphenethylamine (2C-H), N-ethyl-2C-B, etc.[29] act primarily at the 5-HT_{2A} receptors, also displaying low-affinity binding to D₂ receptors and a low inhibitory activity to monoamine transporters (for a thorough review, see Rickli, and colleagues[62]). Adverse effects include headache, dysphoria, hallucinations, mydriasis, seizures, severe agitation, and apnoea. Several related deaths have been reported as well.[1]

Recently, several highly active N-benzyl substituted phenethylamines (NBOMEs) have entered the NPS market and include: 25B-NBOMe ((2-(4-bromo-1,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine)); 25C-NBOMe ((2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine) aka '*N-Bomb*'/'*Pandora*'); and 25I-NBOMe ((4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine) aka '*N-bomb*'). [29,63,64] *In vitro* receptor studies have demonstrated that NBOMe compounds act as potent full agonists at the 5-HT_{2A} and 5-HT_{2C} receptors.[65]

In addition, 25I-NBOMe and 25C-NBOMe are pharmacologically active at very low, sub-milligram, doses.[29] They also display high binding affinity to adrenergic α_{1A} and α_{2A} , as well as histamine H₁, receptors. They show as well low-affinity binding levels to D₂ and D₃ receptors.[62] Their higher 5-HT_{2A} receptor affinity, compared to the 2C- derivatives, explain the frequent associated reports of hallucinations and delusions. NBOMe-containing products are usually available as tablets, capsules, powder, liquid, spray, and blotters. They are usually taken sublingually/orally or via nasal insufflation.[29] Some of them are sold as LSD replacement.[29,63] Depending on the route of administration, their effects may last 3-10 hours. Psychotropic effects

commonly reported include euphoria, increased sociability, visual/auditory/olfactory/tactile perceptual disturbances, empathy, depersonalization, dissociation and derealization. Their adverse effects may include nausea, vomiting, headache, panic/severe agitation, aggressiveness, seizures, insomnia, muscle rigidity/rhabdomyolysis with renal failure, tremors and cardiopulmonary arrest.[29,63] Several fatalities have been reported following the intake of NBOMe compounds.[66]

Benzofurans, which are phenethylamines structurally related to MDMA and MDA (3,4-methylenedioxyamphetamine), include several compounds, e.g.: 6-APB (6-(2-aminopropyl) benzofuran; aka '*BenzoFury*'); 5-APB (5-(2-aminopropyl)benzofuran); 6-APDB (6-(2-Aminopropyl)-2,3-dihydrobenzofuran; aka '*4-Desoxy-MDA*'); 5-APDB (5-(2-Aminopropyl)-2,3-dihydrobenzofuran; aka '*3-Desoxy-MDA*'); etc.[29] They are typically ingested, since nasal insufflation may be painful. Their intake may be associated with stimulant, entactogenic and hallucinogenic effects. Adverse effects may include: dry mouth, nausea, jaw/teeth clenching, insomnia, diarrhoea, light hypersensitivity, hot flushes, headache, drowsiness, panic attacks/anxiety, depression, severe paranoia and psychosis. An unpleasant 'come-down', lasting several days, has been reported.[67] Several deaths related to 5- and 6-APB have been identified.[68]

Tryptamines

Tryptamines have been classified in two groups: a) '*simple tryptamines*', structurally derived from tryptamine; and b) '*ergolines*', structurally related to the semi-synthetic lysergic acid diethylamide/LSD.[69]

Simple tryptamines

Apart from *N,N*-dimethyltryptamine (DMT); other tryptamine derivatives include: 5-MeO-DMT/5-methoxy-*n,n*-dimethyltryptamine, found in some *Delosperma* species; psilocybin (4-phosphoryloxy-*N,N*-dimethyltryptamine); and psilocin (4-hydroxy-*N,N*-dimethyltryptamine), which are identified in hallucinogenic fungi (aka '*magic shrooms*' or '*mushies*'); bufotenin (5-hydroxy-*N,N*-dimethyltryptamine/5-OH-DMT); and 5-hydroxy-indolethylamines, common constituents of venoms of the genre *Hyla*, *Leptodactylus*, *Rana* and *Bufo alvarius*. [70] Tryptamines psychoactive effects are due to their agonism at 5-HT_{1A}, 5-HT_{2A} and 5-HT_{2C} receptors. [71] Other receptors implicated in the tryptamine pharmacodynamics include vesicular monoamine transporter 2 (VMAT2), σ -1, serotonin transporter (SERT) and traceamine-associated (TAR) receptors. [71]

DMT (aka '*Dimitri*'/'*businessman's trip*') has been found in the leaves of *Psychotria viridis*, which are traditionally combined by the indigenous Amazonian tribes with *Banisteriopsis caapi*, source of the monoamine oxidase inhibitors (MAOi) β -carboline alkaloids harmine, harmaline and tetrahydroharmine, to produce Ayahuasca. DMT has been also found in other plant sources, e.g. *Phalaris arundinacea* and *Mimosa hostilis*. [72] DMT produces strong hallucinogenic LSD-like effects, powerful entheogenic experiences/intense visual hallucinations, and euphoria. Since DMT is inactive after oral administration unless combined with MAOis, it is usually injected, snorted, or smoked. If smoked, its effects last for a short period of time (5-30 minutes). [73]

Psilocin hallucinogenic effects occur within the first 2 hours after oral intake and last up to 4-8 hours.[74] Psilocin is a partial 5-HT_{2A} agonist, with little dopaminergic or noradrenergic activity.[75,76]

Bufotenin (aka '*5-OH-DMT*') is found in the skin of various species of the toad *Bufo* genus; in mushrooms such as *Amanita*; and in plants such as *Anadenanthera* and *Piptoderma peregrina*.[77] It acts on 5-HT_{2A} receptors.[78]

Alongside these naturally occurring tryptamines, a rapidly increasing number of tryptamine derivatives, such as: 5-Meo-DALT (N-diallyl-5-methoxytryptamine); AMT (α -methyltryptamine); AET (α -ethyltryptamine); 5-Meo-AMT (5-methoxy- α -methyltryptamine); 4-HO-DALT (N,N-diallyl-4-hydroxytryptamine); 5-MeO-DIPT (5-methoxy-diisopropyl-tryptamine; aka '*foxy*' or '*foxy methoxy*'); DET (N,N-diethyltryptamine); and 5-IT (5-(2-aminopropyl)indole); have recently entered the market. These tryptamine derivatives are usually available as capsules, tablets, powder or liquid formulations and may be ingested, snorted, smoked or injected.[41] The main clinical effects are visual hallucinations, alterations in sensory perception, intensification of colours, distortion of body image, depersonalization, marked mood lability, euphoria, relaxation, entactogenic properties, and anxiety.

Adverse effects include agitation, tachyarrhythmias, hyperpyrexia, serotonergic neurotoxicity and death.[41]

AMT (aka '*Day Tripper*'/IT-290) and AET (aka '*Love Pearls*'/ET) possess central stimulant and hallucinogenic properties. AMT desired effects, peaking in 3-4 hours and lasting up to 12-24 hours, include: euphoria, distortion of

colour/shapes and visual hallucinations. AET is a reversible MAOI and 5-HT/DA releasing molecule. AET onset of action occurs within 30-90 minute; its adverse effects may include: facial flushing, headache, gastrointestinal disorders, irritability, insomnia and, at times, hyperthermia and agitated delirium. Although it may be made available as an LSD alternative, due to its amphetamine-like structure 5-MeO-AMT presents with a range of sympathomimetic effects. It owns a strong binding activity at 5-HT_{1A} and 5-HT_{2A} receptors whilst inhibiting as well the monoamines' reuptake.[79] 5-MeO-DIPT (aka 'foxy/'foxy methoxy'/5MEO), structurally related to DMT and bufotenin, is an agonist at 5-HT_{2A}, 5-HT_{1A}, and 5-HT_{2C} receptors. Its adverse effects include nausea, vomiting, mydriasis, auditory and visual hallucinations, formication, tachycardia, hypertension, echolalia, paranoia, restlessness/agitation and muscle tension.[36] DET significantly inhibits monoamine oxidase. It produces hallucinogenic effects similar to DMT or mescaline. Adverse effects include anxiety, tremors, nausea/vomiting, mydriasis, disinhibition, visual distortions and increased blood pressure.

Ergolines

LSA has been found in the seeds of *Argyrea nervosa* and *Ipomoea violacea*. It is traditionally used during shamanic and ceremonial practices. LSD appears as a crystalline powder soluble in water which is made available as sugar cubes or small squares of papers or stamps ('microdots') which are typically ingested. Its effects are rapid and include headache, raised pulse rate, dilated pupils, nausea, blood pressure alterations and sometimes an increase in body temperature. Its effects vary according to both the subject expectation/mood

and the setting, including idiosyncratic perceptual disturbances such as: stationary objects appearing to move and changing shape; synesthesia; distortions of body image and perception of time etc. Tolerance, dependence and withdrawal experiences have been described by users. Adverse effects may include '*bad trips*', i.e. an unpleasant, often terrifying, post-intake drug experience. Spontaneous recurrence of the drug-induced experience (i.e. flashbacks) is fairly common after LSD use. Some novel LSD derivatives have recently reached the market, such as: LSZ (lysergic acid 2,4-dimethylazetidide); 1-P-LSD (1-propionyl-d-lysergic acid diethylamide hemitartrate) ; ETH-LAD (6-ethyl-6-nor-lysergic acid diethylamide); PRO-LAD (6-propyl- 6-nor-lysergic acid diethylamide), and AL-LAD (6-allyl-6-nor-lysergic acid diethylamide). They produce effects resembling those of LSD, having similar pharmacological action at 5-HT_{2A}-receptors, but possessing different potencies, kick-off effects and duration. [29]

Expert Commentary: NPS use as a clinical challenge for emergency physicians
The constantly and rapidly evolving NPS drug scenario represents a challenge for medicine, and especially so for both emergency physicians and mental health professionals. Indeed, NPS intake is typically associated with the imbalance of a range of neurotransmitter pathways/receptors. Hence, this may be followed by a range of psychopathological disturbances [1], whose occurrence has been related to : a) increased central dopamine levels, associated with the intake of most of these substances, including novel psychedelic phenethylamines, stimulants, synthetic cathinones and 4,4'-DMAR;

b) cannabinoid CB1 receptor activation, achieved with synthetic cannabimimetics; and c) intense 5-HT_{2A} receptor activation, reported with both NBOMe compounds and latest tryptamine derivatives.

Due to the NPS complex pharmacodynamics here described, levels of debate are currently occurring in formal clinical fora to identify a range of proper, NPS-focused, management/treatment strategies. In fact, NPS consumers may present overnight to accident and emergency departments without disclosing their drug intake whilst it is also likely that the standard drug tests will show negative results. It is problematic to draw a detailed and universal management plan to cope with the behavioural and psychopathological disturbances related to the intake of the virtually few hundreds of substances currently available.[80] However, according to Velez and Benitez,[81] the initial management of these patients should focus on decreasing levels of both self/outward-directed aggression and agitation. Verbal de-escalation can always be considered with more cooperative patients. However, given the complex, and at times unknown, pharmacology of the substances possibly ingested by the client, benzodiazepines may be considered as agents of choice.[1] Initially, due to lack of patient cooperation, the intravenous/IV access may be problematic. In those cases, Velez and Benitez have suggested to use either intramuscular/IM or intranasal midazolam (5-10 mg IM/intranasal or 2.5-5mg IV), because of its fast absorption/onset of action; or lorazepam (4-8 mg IM; 2-4 mg IV).[81] Diazepam should only be used IV, as it presents with erratic IM absorption.[81] Benzodiazepines, however, need frequent re-

dosing/high dosages to achieve adequate sedative effect, and this may be a problem if clients have co-ingested alcohol.

Where patients cannot be controlled with benzodiazepines alone, propofol and/or antipsychotics (especially when paranoia and psychosis are being identified) may be considered, although this may further contribute to the acute toxicity effects of the abused substances. Both haloperidol and droperidol (5-10 mg IM or IV) have been suggested as reasonable options.[81] Aripiprazole, quetiapine, risperidone, and olanzapine can also be used, although the levels of evidence regarding their use for the undifferentiated agitation patient is limited.[81]

Treatment of hyperthermia needs to be aggressively planned, and this typically involves cooling measures and, once an IV line is available, focus should be on control of rhabdomyolysis with intravenous fluid administration.[1; 81] The serotonin syndrome is managed using benzodiazepines and cyproheptadine.[1] Inpatient admission, possibly to intensive care units, may at times be needed.

Five-year view

Indeed, future studies will provide better levels of NPS clinical and basic pharmacology-related knowledge, so that better tailored management/treatment guidelines can be made available.

Health professionals' education involving knowledge on NPS health harms, potential interventions, and referral pathways is lacking. Future NPS-related tutoring activities will allow clinicians to promote health prevention and education activities, which in turn would reduce the negative social impact of

NPS misuse; unnecessary hospital admissions; and avoidable fatalities. [82]

Future approaches will consider as well the role of web-based preventative strategies in targeting youngsters/vulnerable individuals at risk of approaching the NPS market.

Although current general population surveys suggest relatively low levels of NPS use, at least if compared with well-known scheduled substances such as THC, cocaine and heroin, this may change. The online market of novel psychoactive substances is unfortunately developing far more rapidly than academic research. Hence, it is more than likely that over the next 5 years or so the number of NPS will continue to rise. Similarly to Poland and Ireland, however, a brand new legislation focussing on NPS is expected to come into effect in the UK in April 2016. As a result of this, it is speculated that most of the so called 'legal highs'/'research chemicals', now considered as technically 'legal', will be outlawed. Since at present a sizeable proportion of the NPS are made available to customers through the most popular 'open web' search engines, one could hypothesize that over the next few years the NPS market will gradually expand and/or move to the 'deep web', and especially to its most hidden portion, e.g. the 'DarkNet'. [2] It is hence here speculated that most transactions of NPS will occur in the future with the help of both 'ad hoc', deep-web tailored, browsers and a range of 'crypto currencies', some of which are already available for use. Current research activities, coordinated from our group, are already focussing on these possible future scenarios.

Key issues

- Over the last decade, the drug scenario has shown significant levels of changes, with the emergence of a range of novel psychoactive substances (NPS). The web may play a major role in shaping this unregulated market
- An overview of the clinical pharmacological issues related to some of the most popular NPS categories, e.g. stimulants (e.g. synthetic cathinones; 4-4-DMAR; methylphenidate-like NPS; amphetamine-type stimulants; aminoindanes; and cocaine analogues); and hallucinogens (synthetic cannabimimetics; psychedelic phenethylamines and tryptamines) is here provided (see Table 1).
- NPS intake is typically associated with the imbalance of a range of neurotransmitter pathways/receptors, which in turn may be followed by the occurrence of a range of psychopathological disturbances, due to: a) increased central dopamine levels, associated with the intake of most of these substances, including novel psychedelic phenethylamines, stimulants, synthetic cathinones and 4,4'-DMAR; b) cannabinoid CB1 receptor activation, achieved with synthetic cannabimimetics; and c) intense 5-HT_{2A} receptor activation, reported with both NBOMe compounds and latest tryptamine derivatives.

- NPS intake usually fails to be identified with standard drug screening tests. Advanced tests can be performed, but they are not generally available in the acute setting and are used mainly for forensic investigations.
- The initial management of these patients should focus on decreasing levels of both self-/outward-directed aggression and agitation. Due to the complex, and at times unknown, pharmacology of the NPS/other psychoactives ingested by the client, benzodiazepines may be considered as agents of choice
- It is more than likely that over the next 5 years or so the number of NPS will continue to rise. A brand new legislation focussing on NPS is expected to come into effect in in the UK April 2016. It is speculated that over the next few years the NPS market will gradually expand and/or move to the 'deep web', and especially to its most hidden portion, e.g. the 'DarkNet'.

Declaration of Interest:

This paper was supported in part by grants of the European Commission (Drug Prevention and Information Programme 2014-16, contract no.

JUST/2013/DPIP/AG/4823, *EU-MADNESS project*). Further financial support

was provided by the EU Commission-targeted call on cross border law

enforcement cooperation in the field of drug trafficking - DG Justice/DG

Migrations and Home Affairs (JUST/2013/ISEC/DRUGS/AG/6429) *Project*

EPS/NPS (Enhancing Police Skills concerning Novel Psychoactive Substances;

NPS). F Schifano is a ACMD member, UK; EMA Advisory Board Member. JM

Corkery is a ACMD UK NPS group advisor. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

References

Papers of special note have been highlighted as:

* of interest

** of considerable interest

1.** A comprehensive and updated review, specifically focussing on psychopathological/neurobehavioural signs and symptoms related to NPS misuse; the paper provides as well an in-depth pharmacological understanding of many different NPS classes.

Schifano F, Orsolini L, Papanti GD, Corkery JM. Novel psychoactive substances of interest for psychiatry. *World Psychiatry* 2015;14:15-26

2.* Interesting netnographic systematic research on the 'e-psychnauts', a growing population of NPS misusers.

Orsolini L, Papanti GD, Francesconi G, Schifano F. Mind navigators of chemicals' experimenters? A web-based description of e-psychnauts. *Cyberpsychol Behav Soc Netw* 2015;18:296-300

3. Deluca P, Davey Z, Corazza O, et al. Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project. *Prog Neuropsychopharmacol Biol Psychiatry* 2012; 39:221-6
4. Simmler LD, Buser TA, Donzelli M, et al. Pharmacological characterization of designer cathinones in vitro. *Br J Pharmacol* 2013; 168:458-70
5. De Felice LJ, Glennon RA, Negus SS. Synthetic cathinones: Chemical phylogeny, physiology, and neuropharmacology. *Life Sci* 2014; 97(1):20-6
6. Baumann MH, Ayestas MA Jr, Partilla JS, et al. The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. *Neuropsychopharmacol* 2012; 37:1192-203
7. Baumann MH, Partilla JS, Lehner KR, et al. Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products. *Neuropsychopharmacol* 2013; 38:552-62
8. Gregg RA, Rawls SM. Behavioral pharmacology of designer cathinones: a review of the preclinical literature. *Life Sci* 2014; 97:27-30
9. * A very interesting paper describing a range of pre-clinical experiments focussing on a range on most recent NPS

Iversen L, White M, Treble R. Designer psychostimulants: pharmacology and differences. *Neuropharmacol* 2014;87:59-65

10. ** A comprehensive and open access guidance on the management of harms related to Club Drugs and NPS intake.

Abdulrahim D, Bowden-Jones O, on behalf of the NEPTUNE Expert Group. Guidance on the Management of Acute and Chronic Harms of Club Drugs and Novel Psychoactive Substances. London: Novel Psychoactive Treatment UK Network, 2015. Available at: <http://neptune-clinical-guidance.co.uk/wp-content/uploads/2015/03/NEPTUNE-Guidance-March-2015.pdf> [Last accessed 14 February 2016]

11. ** A ground breaking paper describing in detail the mephedrone clinical pharmacology issues

Farrè M, Papaseit E, Pérez-Mañá C et al. Human pharmacology of mephedrone: a dose-finding pilot study. San Juan: College on Problems of Drug Dependence Meeting, 2014

12. Schifano F. Novel psychoactive substances also known as 'legal highs'. Annual report of the Chief Medical Officer 2013. Public mental health priorities: investing in the evidence. London: Department of Health, 2014. Available

at: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/413196/CMO_web_doc.pdf [Last accessed 22 November 2015]

13. Schifano F, Corkery J, Ghodse AH. Suspected and confirmed fatalities associated with mephedrone (4-methylmethcathinone; 'meow meow') in the UK. *J Clin Psychopharmacol* 2012;32:710-4

14. Corkery JM, Schifano F, Ghodse AH. Mephedrone-related fatalities in the United Kingdom: contextual, clinical and practical issues. *Pharmacology*. InTech - Open Access Publisher. Rijeka, Croatia, 2012. Available at: <http://www.intechopen.com/books/pharmacology/mephedrone-related-fatalities-in-the-united-kingdom-contextual-clinical-and-practical-issues> [Last accessed 15 November 2015]

15. Corkery JM, Schifano F, Oyefeso A, et al. 'Bundle of fun' or 'bunch of problems'? Case series of khat-related deaths in the UK. *Drugs: Educ Prev Polic* 2011;18:408-25

16. Loi B, Corkery JM, Claridge H, et al. Deaths of individuals aged 16-24 years in the UK after using mephedrone. *Hum Psychopharmacol* 2015;30:225-32

17. Schifano F, Albanese A, Fergus S, et al. Psychonaut Web Mapping; ReDNet Research Groups. Mephedrone (4-methylmethcathinone; 'meow

meow'): chemical, pharmacological and clinical issues. *Psychopharmacol* 2011;214:593-602

18. EMCDDA. Perspectives on drugs: injection of synthetic cathinones. Perspectives on Drugs Series. European Monitoring Centre for Drugs and Drug Addiction. Lisbon, 2014. Available

at: <http://www.emcdda.europa.eu/topics/pods/synthetic-cathinones-injection> [Last accessed 30 November 2015]

19. Giese C, Igoe D, Gibbons Z, et al. Injection of new psychoactive substance snow blow associated with recently acquired HIV infections among homeless people who inject drugs in Dublin, Ireland, 2015. *Euro Surveill* 2015;20(40). doi: 10.2807/1560-7917.ES.2015.20.40.30036

20. Bourne A, Reid D, Hickson F, et al. The Chemsex study: drug use in sexual settings among gay & bisexual men in Lambeth, Southwark & Lewisham. Sigma Research, London School of Hygiene & Tropical Medicine, London 2014. Available

at: <https://www.lambeth.gov.uk/sites/default/files/ssh-chemsex-study-final-main-report.pdf> [Last accessed 30 november 2015]

21. ONS. Deaths related to drug poisoning in England and Wales, 2014 registrations release. Office for National Statistics. Newport, Gwent, 2015.

Available at: http://www.ons.gov.uk/ons/dcp171778_414574.pdf

[Last accessed 30 November 2015]

22. EMCDDA. EMCDDA–Europol Joint Report on a new psychoactive substance: 4,4'-DMAR (4-methyl-5-(4-methylphenyl)-4,5-dihydrooxazol-2-amine). European Monitoring Centre for Drugs and Drug Addiction.

Luxembourg, 2014. Available at:

http://www.emcdda.europa.eu/attachements.cfm/att_229825_EN_TDAS14006ENN.pdf [Last accessed 13 March 2016]

23. ACMD. Methylphenidate-based NPS: A review of the evidence of use and harm. 2015. Available

at: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/420983/TCDO_methylphenidate_NPS.pdf [Last accessed 17 January 2016]

24. Wedinos. 2016. Available

at: <http://www.wedinos.org/db/samples/search> [Last accessed 17 January 2016]

25. TripSit. 2016. Available at: <http://drugs.tripsit.me/ethylphenidate>

[Last accessed 17 January 2016]

26. PsychonautWiki. 2016. Available

at: <https://psychonautwiki.org/wiki/Ethylphenidate> [Last accessed 17 January 2016]

27. Ho JH, Bailey GP, Archer JR, et al. Ethylphenidate: availability, patterns of use, and acute effects of this novel psychoactive substance. *Eur J Clin Pharmacol* 2015; 71:1185-96

28. Soussan C, Kjellgren A. "Chasing the high" - experiences of ethylphenidate as described on international internet forums. *Subst Abuse* 2015; 9:9-16

29. EMCDDA. New psychoactive substances in Europe - An update from the EU Early Warning System. European Monitoring Centre for Drugs and Drug Addiction. Publications Office of the European Union. Luxembourg, 2015. Available at: <http://www.emcdda.europa.eu/publications/2015/new-psychoactive-substances> [Last accessed 15 November 2015]

30. Barratt MJ, Allen M, Lenton S. "PMA sounds fun": negotiating drug discourses online. *Subst Use Misuse* 2014; 49:987-98

31. Di Renzo G, Amoroso S, Tagliatela M, et al. Pure uptake blockers of dopamine can reduce prolactin secretion: studies with diclofenazine. *Life Sci* 1988; 42:2161-9

32. Nakachi N, Kiuchi Y, Inagaki M, et al. Effects of various dopamine uptake inhibitors on striatal extracellular dopamine levels and behaviours in rats. *Eur J Pharmacol* 1995; 281:195-203

33. Blicke FF, Burckhalter JH. "α-Thienylaminoalkanes". *J Am Chem Soc* 1942; 64:477-80

34. Angelov D, O'Brien J, Kavanagh P. The syntheses of 1-(2-thienyl)-2-(methylamino) propane (methiopropamine) and its 3-thienyl isomer for use as reference standards. *Drug Test Anal* 2013;5:145–9

35. Bouso ED, Gardner EA, O'Brien JE, et al. Characterization of the pyrolysis products of methiopropamine. *Drug Test Anal* 2013;6:676-83

36. Erowid.org. 2014. Available at: www.erowid.org [Last accessed 28 September 2014]

37. Iversen L, Gibbons S, Treble R, et al. Neurochemical profiles of some novel psychoactive substances. *Eur J Pharmacol* 2013;700:147-51

38. UNODC. Aminoindanes. 2015. Available at: <https://www.unodc.org/LSS/SubstanceGroup/Details/8fd64573-c567-4734-a258-76d1d95dca25> [Last accessed 7 February 2016]

39. Johnson MP, Frescas SP, Oberlender R, Nichols DE. Synthesis and pharmacological examination of 1-(3-methoxy-4-methylphenyl)-2-aminopropane and 5-methoxy-6-methyl-2-aminoindan: similarities to 3,4-(methylenedioxy)methamphetamine (MDMA). *J Med Chem* 1991;34:1662-8

40. Monte AP, Marona-Lewicka D, Cozzi NV, Nichols DE. Synthesis and pharmacological examination of benzofuran, indan, and tetralin analogues of 3,4-(methylenedioxy)amphetamine. *J Med Chem* 1993;36:3700-6

41. * A reference textbook of interest for both preclinical scientists and clinicians as well

Dargan PI, Wood DM. Novel psychoactive substances: classification, pharmacology and toxicology. London: Academic Press/Elsevier, 2013

42. Corkery JM, Elliott S, Schifano F, et al. MDAI (5,6-methylenedioxy-2-aminoindane; 6,7-dihydro-5H-cyclopenta[f][1,3]benzodioxol-6-amine; 'sparkle'; 'mindy') toxicity: a brief overview and update. *Hum Psychopharmacol* 2013;28:345-55

43. Carroll FI, Gao Y, Rahman P, et al. Synthesis, ligand binding, QSAR, and CoMFA study of 3b-(p-substituted phenyl)tropane- 2b-carboxylic acid methyl esters. *J Med Chem* 1991;34:2719-25

44. Fleckenstein AE, Kopajtic TA, Boja JW, et al. Highly potent cocaine

analogs cause long-lasting increases in locomotor activity. *Eur J Pharmacol* 1996; 311:109-14

45. Carroll FI, Blough BE, Nie Z, et al. Synthesis and monoamine transporter binding properties of 3-(3',4'-disubstituted phenyl)- tropane-2-carboxylic acid methyl esters. *J Med Chem* 2005; 21:2767-71

46. * This paper provides a systematic overview of synthetic cannabimimetics' pharmacology, toxicology, prevalence of use, whilst discussing a wide range of adverse effects /clinical manifestations related to their intake.

Papanti D, Orsolini L, Francesconi, Schifano F. 'Noids' in a nutshell: everything you (don't) want to know about synthetic cannabimimetics. *Adv Dual Diagn* 2014; 7: 137–148

47. ** This preclinical study is of utmost interest: it shows that the new generations of synthetic cannabimimetics possess greater affinity, potency and higher intrinsic affinity than older full agonist compounds; these compounds directly increase the NAc shell dopamine.

De Luca MA, Castelli MP, Loi B, et al. Native CB1 receptor affinity, intrinsic activity and accumbens shell dopamine stimulant properties of third generation SPICE/K2 cannabinoids: BB-22, 5F-PB-22, 5F-AKB-48 and STS-135. *Neuropharmacology* 2015: published online 11 December 2015, doi: 10.1016/j.neuropharm.2015.11.017

48. Brents LK, Prather PL. The K2/Spice Phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products. *Drug Metab Rev* 2014; 46:72–85
49. Fisar Z. Cannabinoids and monoamine neurotransmission with focus on monoamine oxidase. *Prog Neuropsychopharmacol Biol Psychiatry* 2012; 38:68–77
50. Franklin JM, Carrasco GA. Cannabinoid receptor agonists upregulate and enhance serotonin _{2A} (5-HT_(2A)) receptor activity via ERK1/2 signaling. *Synapse* 2013; 67:145-59
51. Morgan D, Kondabolu K, Kuipers A, et al. Molecular and behavioral pharmacology of two novel orally-active 5HT2 modulators: potential utility as antipsychotic medications. *Neuropharmacology* 2013; 72:274-81
52. Daly M. Streets legal. *Druglink* 2013; 28: 17
53. Schifano F, Corazza O, Davey Z, et al. Psychoactive drug or mystical incense? Overview of the online available information on Spice products. *Int J Cult Ment Health* 2009; 2:137-44
54. * A research paper of interest, highlighting the characteristics and

psychopathological consequences of NPS use

Martinotti G, Lupi M, Acciavatti A, et al. Novel Psychoactive Substances in Young Adults with and without Psychiatric Comorbidities. *Biomed Res Int* 2014: published online 15 July 2014, doi: 10.1155/2014/815424

55. Fantegrossi WE, Moran JH, Radomska-Pandya A, Prather PL. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ^9 -THC: Mechanism underlying greater toxicity? *Life Sci* 2014;**97**:45-54

56. *This interesting review discusses the association between 'Spice' misuse and psychotic disorders.

Papanti D, Schifano F, Botteon G, et al. 'Spiceophrenia': A Systematic Overview of 'Spice'-Related Psychopathological Issues and a Case Report. *Hum Psychopharmacol* 2013;**28**:379–89

57. Ustundag MF, Ozhan Ibis E, Yucel A, Ozcan H. Synthetic cannabis-induced mania. *Case Rep Psychiatry* 2015: published online 9 March 2015, doi: 10.1155/2015/310930

58. Kroll D. Scientists Speculate On What Caused The Bial Drug Testing Tragedy In France. *Forbes* 2016. Available

at: <http://www.forbes.com/sites/davidkroll/2016/01/18/scientists-speculate-on-what-caused-the-bial-drug-testing-tragedy-in-france/#44142708301f> [Last

accessed 31 January 2016]

59. Shulgin AT, Manning T, Daley PF. The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds. Berkeley: Transform Press, 2011
60. Corazza O, Schifano F, Farre M, et al. Designer drugs on the internet: a phenomenon out-of-control? the emergence of hallucinogenic drug Bromo-Dragonfly. *Curr Clin Pharmacol* 2011; 6: 125-9
61. O'Connor RE, Keating JJ. Characterization of synthetic routes to 'Bromo-DragonFLY' and benzodifuranyl isopropylamine homologues utilizing ketone intermediates. Part 1: synthesis of ketone precursors. *Drug Test Anal* 2014; 6: 658-67
62. Rickli A, Hoener MC, Liechti ME. Monoamine transporter and receptor interaction profiles of novel psychoactive substances: para-halogenated amphetamines and pyrovalerone cathinones. *Eur Neuropsychopharmacol* 2015; 25: 365-76
63. Bersani FS, Corazza O, Albano G, et al. 25C-NBOMe: preliminary data on pharmacology, psychoactive effects and toxicity of a new potent and dangerous hallucinogenic drug. *Biomed Res Int* 2014: published online 3 July 2014, doi: 10.1155/2014/734749

64. Wood DM, Sedefov R, Cunningham A, Dargan PI. Prevalence of use and acute toxicity associated with the use of NBOMe drugs. *Clin Toxicol (Phila)* 2015;53:85-92
65. Braden MR, Parrish JC, Naylor JC, Nichols DE. Molecular interaction of serotonin 5-HT_{2A} receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists. *Mol Pharmacol* 2006;70:1956–64
66. Lowe LM, Peterson BL, Couper FJ. A Case Review of the First Analytically Confirmed 25I-NBOMe-Related Death in Washington State. *J Anal Toxicol* 2015;39:668-71
67. Jebadurai J, Schifano F, Deluca P. Recreational use of 1-(2-naphthyl)-2-(1-pyrrolidiny)-1-pentanone hydrochloride (NRG-1), 6-(2-aminopropyl) benzofuran (benzofury/6-APB) and NRG-2 with review of available evidence-based literature. *Hum Psychopharmacol* 2013;28: 356–64
68. Elliott S, Evans J. A 3-year review of new psychoactive substances in casework. *Forensic Sci Int* 2014;243:55-60
69. AMCD. Update of the Generic Definition for Tryptamines. 2014. Available at: https://www.gov.uk/government/uploads/system/uploads/attachment_data

<a/file/318693/UpdateGenericDefinitionTryptamines.pdf> [Last Accessed 13 February 2016]

70. Collins M., Some new psychoactive substances: precursor chemicals and synthesis-driven end-products. *Drug Test Anal* 2011;3:404-16

71. Pierce PA, Peroutka SJ. Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex. *Psychopharmacol* 1989;97:118–22

72. Shulgin AT, Shulgin A. TIHKAL: the continuation. Berkeley: Transform Press, 1997

73. Araújo AM, Carvalho F, de Lourdes Bastos M, et al. The hallucinogenic world of tryptamines: an updated review. *Arch Toxicol* 2015; 89:1151–73.

74. Halpern JH. Hallucinogens and dissociative agents naturally growing in the United States. *Pharmacol Ther* 2004;102:131– 138

75. Peden NR, Macaulay KEC, Bisset AF, et al. Clinical toxicology of 'magic mushroom' ingestion. *Postgrad Med J* 1981;57:543-45

76. Hill SL, Thomas SH. Clinical Toxicology of newer recreational drugs. *Clin Toxicol* 2011;49:705-19

77. Lyttle T, Goldstein D, Gartz J. Bufo. Toads and bufotenine: fact and fiction surrounding an alleged psychedelic. *J Psychoactive Drugs* 1996;28:267–90

78. Ujvary I. Psychoactive natural products: overview of recent developments. *Ann Ist Super Sanità* 2014;50:12-27

79. Nagai F, Nonaka R, Satoh Hisashi Kamimura K. The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. *Eur J Pharmacol* 2007;559:132–37

80. Schifano F. Novel psychoactive substances (NPS): clinical and pharmacological issues. *Drugs Alcohol Today* 2015;15:21-7

81. Velez L, Benitez F. New Troublesome Drugs: The Synthetics. Available at: <http://www.emdocs.net/new-troublesome-drugs-the-synthetics> [Last accessed 4 February 2016]

82. Guirguis A, Corkery JM, Stair JL, et al. Survey of knowledge of legal highs (novel psychoactive substances) amongst London pharmacists. *Drugs Alcohol Today* 2015;15:93–9

Table 1: Stimulant and hallucinogenic novel psychoactive substances (NPS); chemical structure; pharmacodynamics; gergal/colloquial names; psychoactive effects and medical/psychopathological consequences

Stimulant NPS

Class	Structure	Action	Gergal/colloquial names	Psychoactive effects and medical/psychopathological consequences
Synthetic cathinones	Analogues of beta-ketoamphetamine cathinone	Substrates for DAT, SERT and NET	'Meow Meow'; 'Bubbles'; Mephedrone; Methylone; MPDV; α -PVP, and many others;	<ul style="list-style-type: none"> Euphoria, mood enhancement; openness; empathy; mental clarity; elation; increased libido; Restlessness; anxiety; hallucinatory experiences; psychosis; Tachycardia; hypertension; abdominal pain; chills; flushing; sweating; hyperthermia; renal failure; rhabdomyolysis; seizures; serotonin syndrome; chronic use: paranoid ideation and mood disturbances;
		Monoamine transporter substrates with DAT-selective profiles		
		Non-substrate transporter inhibitors		
Aminorex derivatives	Para-methyl derivative of 4-methylaminorex and analogues	DA/NA releasing action and SERT inhibition	'Serotoni'; '4,4'-dimethylaminorex/DMAR	<ul style="list-style-type: none"> Elation; increased alertness; anxiety; agitation; Increased body temperature; cardiorespiratory issues;
Methylphenidate-like NPS	Ethyl-homologue of methylphenidate	Potent DAT and NERT inhibition	'El Burst'; 'El Blanco'; Ethylphenidate;	<ul style="list-style-type: none"> Euphoria; elation; increased arousal; improved concentration, sociability, and sexual drive; Muscle tension; palpitations; sweating; appetite loss; anxiety and restlessness; Insomnia; paranoia; hallucinations; Bizarre and violent behaviour; suicidality; psychosis; relapse of psychotic disorder

Novel Amphetamine type stimulants	Analogues of amphetamine and methylamphetamine	Variable levels of SERT, NET and DAT inhibitory potencies	PMA; PMMA; 4-MTA; DMA; MPA; diclofensine	<ul style="list-style-type: none"> Euphoria; increased energy and sexual drive; improved sociability; colour and sound amplification; Increased alertness and anxiety levels; loss of appetite; Tachycardia; increased body temperature
Synthetic cocaine substitutes	Benzoic acid esters	DAT inhibition	Dimethocaine	<ul style="list-style-type: none"> Increased concentration and attention; talkativeness; Tachycardia; diaphoresis; muscle twitching; nausea; vomiting; peripheral vasoconstriction
			<i>p</i> -FBT	<ul style="list-style-type: none"> Hypertension; tachycardia; Anxiety; temporary psychosis;
	3-phenyltropane analogues	SERT, NET and DAT inhibitory properties	RTI-111; RTI-121; RTI-126	<ul style="list-style-type: none"> Euphoria; talkativeness; Increased alertness; anxiety; paranoid ideation; Insomnia; crash-like symptoms
Amino-indanes	Aminoindane analogues	Serotonin release and SERT inhibition	MDAI; 5-IAI; ETAI;	<ul style="list-style-type: none"> Euphoria; elation; mood enhancement; openness, empathy; mental clarity; increased energy and libido; Eye and skin irritation; gastrointestinal, and respiratory disturbances; Serotonin syndrome

DAT: dopamine transporter; SERT: serotonin transporter; NET: norepinephrine transporter

Hallucinogenic NPS

Class	Structure	Action	Gergal/colloquial names	Psychoactive effects and medical/psychopathological consequences
Synthetic cannabimimetics	Large class of compounds with different chemical structures	CB1, CB2 receptor full agonism; 5-HT, nicotinic, glycine, and NMDA receptors' interaction	'Spice'; 'K2'; 'Bonzai'; 'clockwork orange'; 'psyclone'; JWH-018; HU-210; XLR-11; 5F-AKB48; PB-22; ADB-PINACA; MAB-CHMINACA; and many others	<ul style="list-style-type: none"> • Visual and auditory hallucinations; paranoid ideation; • Anxiety/panic attacks; agitation; behavioural dyscontrol; excited delirium; • Suicidal ideation; manic-like symptoms; relapse of bipolar disorders; • Temporary psychosis; relapse of psychotic disorders; persisting psychotic disorders/'Spicephrenia' • Tachycardia; hypertension; dyspnoea/tachypnoea; mydriasis; nausea; vomiting; hypokalaemia; • Acute kidney injuries; myocardial infarction; liver failure; • Nystagmus; seizures; encephalopathy; stroke; • Rhabdomyolysis; hyperthermia; serotonin syndrome possible
Psychedelic phenethylamines	2C-B difuran analogue	5-HT _{2A} agonism; 5-HT _{2B} and 5-HT _{2C} affinity	'Bromodragonfly'	<ul style="list-style-type: none"> • Long standing hallucinations; paranoid ideation; mood elevation; confusion; anxiety; flashbacks; • Convulsions; respiratory issues; liver failure; kidney failure; vasoconstriction;
	2C-B derivatives	5-HT _{2A} affinity; D ₂ low affinity; monoamine transporters' low inhibitory activity levels	'2C-series'; 'Nexus'; 2C-D; 2C-E; 2C-N; 2C-H; and others;	<ul style="list-style-type: none"> • Hallucinations; dysphoria; severe agitation; • Mydriasis; seizures; headache; apnoea
			'N-bomb';	<ul style="list-style-type: none"> • Visual, auditory, olfactory, and tactile

	N-benzyl substituted phenethylamines	5-HT _{2A} and 5-HT _{2C} full agonism; α_{1A} , α_{2A} and H ₁ high binding affinity; D ₂ and D ₃ low-affinity	25B-NBOMe; 25C-NBOMe; 25I-NBOMe	<p>hallucinations;</p> <ul style="list-style-type: none"> Euphoria; increased sociability; empathy; Depersonalisation; dissociation; derealization; Panic; severe agitation; insomnia; aggressiveness; Nausea; vomiting; headache; seizures; muscle rigidity; rhabdomyolysis; tremors; Renal failure; cardiopulmonary arrest;
	MDA benzofuran analogues	5-HT _{2A} and 5-HT _{2B} agonism; DAT, α_{2C} affinity; SERT inhibition	'BenzoFury'; 5-APB; 6-APB; and others	<ul style="list-style-type: none"> Euphoria; elation; entactogenic properties; hallucinations; Agitation; panic attacks; insomnia; Severe paranoia; psychosis; Unpleasant come-down; depression; Nausea; hot flushes; headache; jaw clenching; Serotonin syndrome possible
Tryptamines	Tryptamine derivatives	5-HT _{1A} , 5-HT _{2A} , 5-HT _{2C} agonism; VMAT2, σ -1, SERT, TAR interactions	4-HO-DALT; 5-MeO-DMT; 5-MeO-DIPT; 5-MeO-DALT; and others	<ul style="list-style-type: none"> Visual hallucinations common; auditory hallucinations possible; Intensification of colours; distortion of body image; depersonalization; Euphoria; marked mood lability; relaxation; entactogenic properties; Anxiety; panic disorder; agitation; restlessness; paranoia; excited delirium; Tachyarrhythmia; hyperpyrexia; Hypertension; Nausea; vomiting; muscle tension; Serotonin syndrome possible
Ergolines	LSD-related compounds	5-HT _{2A} agonism and/or other 5-HT ₂ receptors agonism/interactions	LSZ; 1-P-LSD; ETH-LAD; PRO-LAD; AL-LAD;	<ul style="list-style-type: none"> Hallucinations; time distortion; body image alterations; Bad trips; flashbacks; Headache; nausea; mydriasis; tachycardia;

				hyperpyrexia; hypertension
--	--	--	--	----------------------------

DAT: dopamine transporter; SERT: serotonin transporter; NERT: norepinephrine transporter; VMAT2: vesicular monoamine transporter 2;
TAR: traceamine-associated receptors;

ACCEPTED MANUSCRIPT